Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or b2 microglobulin

HIGHLIGHTS

• who: Yutaka Shimazu from the DepartmentKyoto University have published the research work: Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin, in the Journal: Scientific Reports Scientific Reports
• what: This study demonstrated that the simple model using the u03ba/u03bb ratio (or B2MG), and lymphocyte counts easily predicted the durable efficacy of elotuzumab treatment. The study design focused on TTNT to establish a model for predicting patients with a durable response to elotuzumab treatment. This study also showed that the effectiveness of elotuzumab was attenuated by . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.